AZGP1 activation by lenvatinib suppresses intrahepatic cholangiocarcinoma epithelial-mesenchymal transition through the TGF-β1/Smad3 pathway

Intrahepatic cholangiocarcinoma (ICC) is a primary liver malignancy and is characterized by highly aggressive and malignant biological behavior. Currently, effective treatment strategies are limited. The effect of lenvatinib on ICC is unknown. In this study, we found that AZGP1 was the key target of...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Liming, Bao, Wenming, Zhang, Baofu, Zhang, Sina, Chen, Ziyan, Zhu, Xuewen, He, Bangjie, Wu, Lijun, Chen, Xiaohu, Deng, Tuo, Chen, Bo, Yu, Zhengping, Wang, Yi, Chen, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480466/
https://www.ncbi.nlm.nih.gov/pubmed/37669935
http://dx.doi.org/10.1038/s41419-023-06092-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480466/
https://www.ncbi.nlm.nih.gov/pubmed/37669935
http://dx.doi.org/10.1038/s41419-023-06092-5

Ejemplares similares